

TCR $\gamma\delta$

CD3

TCR $\gamma\delta$ /CD3

CD4/CD8


TCR $\gamma\delta$ /CD3

(TCR $\alpha\beta$ + $\gamma\delta$ )

CD4/CD8


**A**

Normal mucosa




**B**

Peyer's patch




**C**


Colon carcinoma



**Fig. S2  
(colon)**



**Fig. S3**  
**(colon)**



**Fig. S4  
(colon)**




Fig. S5  
(colon)




Fig. S6  
(colon)





Fig. S7  
(tonsil)



**Fig. S8  
(tonsil)**




Fig. S9  
(tonsil)




Fig. S10  
(tonsil)











Fig. S11  
(tonsil)





**Fig. S12 (below PBMC digested VS PBMC undigested, under)**





**Fig. S13 (below PBMC digested VS PBMC undigested, under)**





**Fig. S14 (below PBMC digested VS PBMC undigested, under)**



**Fig. S15 (below PBMC digested VS PBMC undigested, under)**



**Fig. S16 (below PBMC digested VS PBMC undigested, under)**



## 1 **Supplementary figure legends**

2 **Supplementary Figure S1. Identification of DN T cells in normal colon and CRC:**  
3 **adjustment steps to final merge.** Stainings are from FFPE of human normal colon mucosa (A),  
4 including Peyer's patches (B), and colon carcinoma (C) biopsies stained as labeled. The original  
5 images were taken as snapshots from digital slides and adjusted changing hues and saturation  
6 for TCR $\delta$  and CD3 that were originally stained using the same red chromogen (they turned  
7 respectively to green and fuchsia; original images are shown in **Figure 1**) in order to highlight  
8 the single markers when images would have been merged. Only saturation was adjusted for  
9 CD4 (brown) and CD8 (blue). Intermediate and final merged images were also shown. Two  
10 normal colic mucosa cases with different number of TCR $\gamma\delta$ <sup>+</sup> cells (A), a representative Peyer's  
11 patch (B) and a representative colon carcinoma with paucity of DN T cells (C) are shown.  
12 Magnification 400x. Scale bar: 69  $\mu$ m.

13 **Supplementary Figure S2. Representative gating strategy for the identification of B**  
14 **lymphocytes, granulocytes, and NK lymphocytes subsets in colon mucosae.** In step 1-3 we  
15 sequentially excluded dead cells (1), debris (2) and doublets (3). Then, we identified  
16 CD45<sup>+</sup>/EpCam<sup>-</sup> cells and CD45<sup>-</sup>/EpCam<sup>+</sup> cells (4). Among CD45<sup>+</sup>/HLA-DR<sup>-</sup> cells (5) we  
17 evaluated granulocytes as CD66b<sup>+</sup>/CD16<sup>+</sup> cells (6). Subsequently, from SSC-A low CD45<sup>+</sup> cells  
18 (7), we identified NK cells (8) and B lymphocytes (9) as CD56<sup>+</sup> and CD19<sup>+</sup> cells, respectively.

19 **Supplementary Figure S3. Representative gating strategy for the identification of pDC**  
20 **subset in colon mucosae.** In step 1-3 we sequentially excluded dead cells (1), debris (2) and  
21 doublets (3). Then, we identified CD45<sup>+</sup>/EpCam<sup>-</sup> cells and CD45<sup>-</sup>/EpCam<sup>+</sup> cells (4).  
22 Subsequently, we identified CD45<sup>+</sup>/HLA-DR<sup>+</sup> cells (5) and considered only CD11c<sup>-</sup>/HLA-DR<sup>+</sup>  
23 cells, excluding the myeloid subset (6). pDCs were gated as CD123<sup>+</sup>/CD303<sup>+</sup> cells (7).

24 **Supplementary Figure S4. Representative gating strategy for the identification of T**  
25 **lymphocytes subset in colon mucosae.** After dead cells, debris and doublets exclusion (step 1-  
26 3), we identified CD45<sup>+</sup>/EpCam<sup>-</sup> cells and CD45<sup>-</sup>/EpCam<sup>+</sup> cells (4). Subsequently, T  
27 lymphocytes were gated as CD45<sup>+</sup>/CD3<sup>+</sup> with low SSC-A scatter (5 and 6). From CD3<sup>+</sup> cells,  
28 we evaluated CD4<sup>+</sup> or CD8<sup>+</sup> T lymphocytes subsets (7).

29 **Supplementary Figure S5. Representative gating strategy for the identification of**  
30 **macrophage subset in colon mucosae.** After dead cells, debris and doublets exclusion (step 1-  
31 3), we identified CD45<sup>+</sup> cells (4) and HLA-DR<sup>+</sup> cells (5). We evaluated myeloid subset as

32 CD11c<sup>+</sup>/HLA-DR<sup>+</sup> cells (6). Monocyte/macrophages subset was gated as CD11b<sup>+</sup>/CD14<sup>+</sup> cells  
33 (7). Macrophages were evaluated as CD14<sup>+</sup>/CD163<sup>++</sup> cells (8).

34 **Supplementary Figure S6. Representative gating strategy for the identification of myeloid**  
35 **cell subsets in colon mucosae.** After dead cells, debris and doublets exclusion (step 1-3), we  
36 identified CD45<sup>+</sup> cells (4) and HLA-DR<sup>+</sup> cells (5). We evaluated myeloid subset as  
37 CD11c<sup>+</sup>/HLA-DR<sup>+</sup> cells (6). Slan-DC subset were gated as Slan<sup>+</sup> and CD14<sup>++</sup> bright cells (7).  
38 CD1c/BDCA-1 and CD141/BDCA-3 dendritic cells were gated as CD11c<sup>+</sup>/CD1c<sup>+</sup> cells (8) and  
39 CD11c<sup>+</sup> /CD141<sup>++</sup> cells (9), respectively.

40 **Supplementary Figure S7. Representative gating strategy for the identification of**  
41 **granulocytes, B lymphocytes and NK cells subsets in tonsils.** In step 1-3 we sequentially  
42 excluded dead cells (1), debris (2) and doublets (3). Then, we identified CD45<sup>+</sup>/EpCam<sup>-</sup> cells  
43 (4). Among CD45<sup>+</sup>/HLA-DR<sup>-</sup> cells (5), granulocytes were gated as CD66b<sup>+</sup>/CD16<sup>+</sup> cells (6).  
44 From SSC-A low CD45<sup>+</sup> cells (7), we identified NK cells (8) and B lymphocytes (9) as CD56<sup>+</sup>  
45 and CD19<sup>+</sup> cells, respectively.

46 **Supplementary Figure S8. Representative gating strategy for the identification of pDC**  
47 **subset in tonsil.** In step 1-3 we sequentially excluded dead cells (1), debris (2) and doublets (3).  
48 Then, we identified CD45<sup>+</sup>/ EpCam<sup>-</sup> cells (4). Among CD45<sup>+</sup>/HLA-DR<sup>+</sup> cells (5), we  
49 considered only CD11c<sup>-</sup>/HLA-DR<sup>+</sup> cells (6).pDCs were gated as CD123<sup>+</sup>/CD303<sup>+</sup> cells (7).

50 **Supplementary Figure S9. Representative gating strategy for the identification of T**  
51 **lymphocytes subset in tonsil.** After dead cells, debris and doublets exclusion (step 1-3), we  
52 identified CD45<sup>+</sup>/EpCam<sup>-</sup> cells (4). Subsequently, T lymphocytes were gated as CD45<sup>+</sup>/CD3<sup>+</sup>  
53 with low SSC-A scatter (5 and 6). From CD3<sup>+</sup> cells, we evaluated CD4<sup>+</sup> or CD8<sup>+</sup> T  
54 lymphocytes subsets (7).

55 **Supplementary Figure S10. Representative gating strategy for the identification of**  
56 **macrophage subset in tonsil.** After dead cells, debris and doublets exclusion (step 1-3), we  
57 identified CD45<sup>+</sup> cells (4) and HLA-DR<sup>+</sup> cells (5). Among CD45<sup>+</sup>/HLA-DR<sup>+</sup> subset, we  
58 evaluated myeloid subset as CD11c<sup>+</sup>/HLA-DR<sup>+</sup> cells (6). Monocyte/macrophages subset was  
59 evaluated as CD11b<sup>+</sup>/CD14<sup>+</sup> cells (7). Macrophages were gated as CD14<sup>+</sup>/CD163<sup>++</sup> cells (8).

60 **Supplementary Figure S11. Representative gating strategy for the identification of**  
61 **myeloid cell subsets in tonsil.** After dead cells, debris and doublets exclusion (step 1-3), we

62 identified CD45<sup>+</sup> cells (4), and HLA-DR<sup>+</sup> cells (5). We evaluated myeloid subset as  
63 CD11c<sup>+</sup>/HLA-DR<sup>+</sup> cells (6). Slan-DC subset were gated as Slan<sup>+</sup> and CD14<sup>++</sup> bright cells (7).  
64 CD1c/BDCA-1 and CD141/BDCA-3 dendritic cells were gated as CD11c<sup>+</sup>/CD1c<sup>+</sup> cells (8) and  
65 CD11c<sup>+</sup>/CD141<sup>++</sup> cells (9).

66 **Supplementary Figure S12. Immunophenotype of B lymphocytes, granulocytes and NK**  
67 **lymphocytes from enzymatically digested PBMCs in comparison with undigested PBMCs.**  
68 Representative gating strategy for the identification of B lymphocytes, granulocytes and NK  
69 lymphocytes in PBMCs shows that there is not any difference between enzymatically treated  
70 (upper panel), like colon mucosae, and undigested PBMCs (lower panel). The gating strategies  
71 are the same to those described for mucosa (figure S2) and tonsil (figure S7).

72 **Supplementary Figure S13. Immunophenotype of pDCs from enzymatically digested**  
73 **PBMCs in comparison with undigested PBMCs.** Representative gating strategy for the  
74 identification of pDC subset in PBMCs shows that there is not any difference between  
75 enzymatically treated (upper panel), like colon mucosae, and undigested PBMCs (lower panel).  
76 The gating strategies are the same to those described for mucosa (figure S3) and tonsil (figure  
77 S8).

78 **Supplementary Figure S14. Immunophenotype of T lymphocytes from enzymatically**  
79 **digested PBMCs in comparison with undigested PBMCs.** Representative gating strategy for  
80 the identification of T lymphocytes subset shows that there is not any difference between  
81 enzymatically treated (upper panel), like colon mucosae, and undigested PBMCs (lower panel).  
82 The gating strategies are the same to those described for mucosa (figure S4) and tonsil (figure  
83 S9).

84 **Supplementary Figure S15. Immunophenotype of macrophages from enzymatically**  
85 **digested PBMCs in comparison with undigested PBMCs.** Representative gating strategy for  
86 the identification of macrophage subset shows that there is not any difference between  
87 enzymatically treated (upper panel), like colon mucosae, and undigested PBMCs (lower panel).  
88 The gating strategies are the same to those described for mucosa (figure S5) and tonsil (figure  
89 S10).

90 **Supplementary Figure S16. Immunophenotype of myeloid cells from enzymatically**  
91 **digested PBMCs in comparison with undigested PBMCs.** Representative gating strategy for  
92 the identification of myeloid cell subsets shows that there is not any difference between

93 enzymatically treated (upper panel), like colon mucosae, and undigested PBMCs (lower panel).  
94 The gating strategies are the same to those described for mucosa (figure S6) and tonsil (figure  
95 S11).